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Abstract. extraocular dissemination is the main cause of death 
in patients with retinoblastoma (rB) in developing countries, 
and there are few molecular markers that are useful for the 
evaluation of minimal disseminated disease. The Gd2 gangli-
oside is known to be expressed by rB cells that metastasize 
in bone marrow, and the activity of the enzyme responsible 
for its synthesis, Gd2 synthase, can be detected in neuroblas-
toma, which shares many phenotypic features with rB. The 
purpose of the present study was to optimize the detection of 
Gd2 synthase expression by reverse transcription-polymerase 
chain reaction (rT-Pcr) followed by nested-Pcr in human 
rB cell lines and patient samples. The optimization strategy 
was carried out using the rB cell lines Y79 and Weri-rb1 
and specific primers designed for the human sequence of GD2 
synthase mrna. We detected Gd2 synthase expression with 
at least 200 and 40 pg of total rna extracted from cultured 
RB cells using a first round of RT-PCR amplification or a 
second round of nested-PCR, respectively. We also confirmed 
the expression of Gd2 synthase by rT-Pcr and immunohis-
tochemical detection of the ganglioside in human rB tumors 
xenotransplanted in nude mice. using tumor bank specimens 
from eight rB patients, we were able to demonstrate the pres-
ence of GD2 synthase mRNA in blood and cerebrospinal fluid 
samples in cases of extraocular dissemination of the tumor. 
The sequence was not detected in samples derived from 
children with low-risk disease or healthy adult volunteers. 
Hence, Gd2 synthase mrna detection through an optimized 
nested rT-Pcr assay is a promising tool for the assessment of 
minimal disseminated disease in enucleated patients.
Introduction
retinoblastoma (rB) is the most common eye cancer in chil-
dren, affecting 1 in 15,000-20,000 births (1) and accounting for 
4% of all pediatric malignancies (2). it is caused by the accu-
mulation of mutations in both alleles of the RB1 gene, the first 
cancer gene identified and cloned in 1986 (3). When it dissemi-
nates outside the eye, it is associated with  a dismal patient 
prognosis. in developing countries with poor education, socio-
economic conditions and health care systems, delayed diagnosis 
and suboptimal care constitute the common scenario (4,5). 
Therefore, while salvage has become a priority in developed 
countries, this is currently not the case in less developed ones, 
where death from RB remains a major issue (6-9). In Argentina 
and other countries with a similar degree of socioeconomic 
development, there is a greater than 80% chance of survival, 
but microscopical invasion of the ocular coats, requiring more 
intensive treatment, is still common. Some of these patients die 
due to extraocular disease after undergoing enucleation when 
adequate post-operative treatment is not provided (5). The risk 
of extraocular relapse is currently estimated by assessing the 
invasion of ocular coats such as the optic nerve, choroid or 
sclera, with adjuvant therapy administered to patients based 
upon this information. However, there is no consensus regarding 
the value of each of these prognostic factors (10,11).
This estimation, based upon histopathological risk factors, 
has a limited sensitivity for identifying patients at risk 
due to minimal disseminated disease (Mdd). Thus, some 
patients needing adjuvant therapy may be overlooked while, 
conversely, some identified as being at a higher risk by histo-
pathology may not need adjuvant therapy, and are therefore 
unnecessarily exposed to the adverse effects of high-dose 
chemotherapy (12-14). Adjuvant therapy usually requires the 
use of high doses of chemotherapy, including drugs with good 
penetration into the central nervous system (15,16), where 
recurrences are more likely.
Since Smith et al first reported the use of the reverse tran-
scription-polymerase chain reaction (rT-Pcr) methodology 
for the amplification of tyrosinase transcripts to detect circu-
lating melanoma cells in peripheral blood samples in 1991 (17), 
molecular detection of MDD utilizing specific target sequences 
has been proposed for several types of cancer (18) due to its high 
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specificity and sensitivity. However, in RB a major obstacle for 
MDD detection is the lack of specific tumor markers. Certain 
gangliosides are the most frequently used molecular markers 
for such a purpose in other pediatric malignancies that share 
a similar antigenic profile with RB, such as neuroblastoma 
(19). Gangliosides are involved in normal biological functions 
including cell adhesion, cell-cell interactions and proliferation 
(20). Specific alterations in the expression of gangliosides after 
neoplastic transformation, which are likely involved in the meta-
static phenotype of malignant cells (21,22), have been found, 
particularly in tumors of neural crest-derived tissues (23).
one of the most extensively studied molecular markers for 
the detection of Mdd in neuroblastoma is the transcript of 
the β1,4-n-acetylgalactosaminyltransferase (Gd2 synthase) 
gene (19,24). GD2 synthase is the key enzyme required for 
the synthesis of the Gd2 ganglioside (25), and is commonly 
expressed in normal tissues such as the brain and in several 
tumor types, as previously mentioned (23).
To date, molecular markers for rB that can be used for 
the determination of Mdd have received little attention in the 
scientific literature, probably since extraocular dissemination 
is uncommon in more developed countries. The finding of 
such a molecular marker for Mdd detection would not only 
allow for more appropriate therapeutic decision making before 
metastasis or a potential recurrence takes place, but would also 
allow for the monitoring of the outcome of patients during 
treatment. The possibility of identifying a high-risk subgroup 
of patients through the detection of this type of marker may 
result in the prevention of metastasis by the selection of a more 
personalized adjuvant therapy. as Gd2 synthase has proven 
to be a useful molecular marker in neuroblastoma, and given 
the fact that the Gd2 ganglioside was found to be shed from 
human RB tumors (26) and was found in the bone marrow of 
rB patients (27), we suggest that it may be a good candidate 
for Mdd detection in rB.
Based on these findings, our aim was to study the expres-
sion of Gd2 at the immunohistochemical level and to detect 
the Gd2 synthase transcript in human rB cell lines and 
patient samples by means of an optimized nested rT-Pcr 
technique. We also pursued the design of novel high-affinity 
primers for this sequence. 
Materials and methods
Cell lines. The human rB cell lines Y79 and Weri-rb1 were 
cultured in suspension in RPMI-1640 medium (Gibco BRL) 
with 20 or 10% heat-inactivated fetal bovine serum (Paa 
laboratories GmbH), respectively. cultures were maintained 
at 37˚C in 5% carbon dioxide and at the appropriate conditions 
of humidity, with change of the culture medium once or twice 
weekly. The culture medium was supplemented (per liter) 
with 2.5 g glucose, 2.38 g HEPES, 1 mM sodium pyruvate, 
1.5 g sodium bicarbonate and 2 ml gentamycin (80 mg/ml) 
as specified by the supplier (ATCC). RNA from other human 
tumor cell lines (McF7 breast, Hela cervical and H125 lung 
human carcinomas) had previously been extracted and stored 
at our laboratory.
Tumor growth in nude mice. Specific pathogen-free athymic 
female nude (nu/nu) Balb/c mice were purchased from the 
animal Facility of unlP (argentina) and maintained in sterile 
isolated conditions. Water and food was given ad libitum. all 
animal protocols were supervised and managed by qualified 
trained personnel according to the international guidelines for 
animal care.
Y79 cells were harvested by centrifugation, washed twice 
and resuspended in RPMI-1640 medium or in 10 mg/ml cold 
liquid Matrigel (BD Biosciences) in a final volume of 250 µl 
at a concentration of 1x106 cells/mouse. Tumor cells were 
immediately inoculated in the subcutis of the flank of nude 
mice with either culture media or Matrigel (28). Animals were 
monitored twice a week for 4 weeks until tumors reached a 
mean diameter of ~10 mm. Tumor tissue from growing tumors 
was either fixed in 10% buffered formalin for immuno-
histochemical studies or rapidly frozen at -70˚C for mRNA 
isolation.
Immunohistochemical detection of ganglioside GD2. 
Formalin-fixed paraffin-embedded tissue blocks of RB tumors 
generated in nude mice were sectioned (3 µm), mounted on 
silanized slides, deparaffinized in xylene, blocked in 3% H2o2 
and processed for antigen retrieval in pre-heated sodium-citrate 
buffer (pH 6.0). The murine anti-GD2 monoclonal antibody 
3F8 was provided by Dr Nai-Kong V. Cheung (Memorial 
Sloan-Kettering, NY, USA). Samples were incubated over-
night with the antibody (1:50) at 4˚C in a moist chamber. 
after washing with Tris-buffer (pH 7.3), a peroxidase-labeled 
polymer conjugated to secondary anti-mouse antibodies 
(dako enVision detection System) was applied, and samples 
were further incubated for 30 min at room temperature and 
developed with diaminobenzidine as the chromogen. Sections 
were counterstained with Mayer's hematoxylin, then dehy-
drated, cleared and mounted.
Sample collection and processing. Peripheral blood (PB), 
cerebrospinal fluid (CSF) and tumor samples from patients 
<5 years of age who had undergone enucleation were obtained 
from the Tumor Bank of the Periatric Hospital Professor 
dr Juan P. Garrahan (Buenos aires, argentina) for use in 
this study. Written informed consent was obtained from all 
patient guardians, and ethical approval was obtained from the 
institutional review Board of the hospital. The patient samples 
and PB samples from healthy adult volunteer donors were 
processed for Gd2 synthase mrna detection. each sample 
was stored in a 1:1.5 ratio of sample:guanidinium thiocyanate 
(GTC) buffer. The buffer contained 6 M GTC (Promega), 
0.0375 M sodium citrate and 0.75% n-lauroylsarcosine. after 
mixing, the sample/GTC mixtures were stored immediately at 
-70˚C until use. In order to achieve a final GTC concentration 
of 4 M (29), 3 ml of PB and cSF extracted from the patients 
was collected directly in 4.5 ml of 6 M GTC buffer. Due to 
the small size, tumor samples were collected in 4 M GTc 
buffer, on the assumption that the amount of samples would 
not affect the buffer concentration.
RNA extraction. rna extraction from cell lines and patient 
samples was conducted at 4˚C based on TRIzol extraction 
methodology (Trizol lS reagent; invitrogen) according to 
the manufacturer's instructions. rna pellets were resuspended 
in a 30-µl final volume of DEPC-treated water and stored at 
Molecular Medicine rePorTS  3:  253-259,  2010 255
-70˚C until use. In the case of small samples such as tumor 
fragments or cSF, we used ultrapure glycogen (invitrogen) as 
a carrier to optimize the extraction. RNA was first quantified 
spectrophotometrically, and its integrity was assessed electro-
phoretically after using the obtained rna as a template for 
glyceraldehyde 3-phosphate dehydrogenase (GaPdH) mrna 
amplification.
Primer design. The design of highly specific primers for the 
human GD2 synthase mRNA sequence (GenBank acces-
sion no. NM_001478) was carried out with PrimerSelect™ 
5.05 software (dnastar inc.), with default settings applied. 
The best score, the lower difference in melting temperature 
between each pair of primers (<1˚C), and the best sequential 
and structural features to prevent intramolecular or inter-
molecular secondary structures were considered. in addition, 
an inter-exonic design was employed, thereby allowing for 
the distinction between the amplification of contaminating 
genomic DNA present in the sample from those amplified 
from the transcripts. Primer details are presented in Table i.
RT-PCR optimization. rna samples were analyzed by a two-
step RT-PCR assay using specific primers for a 347-bp GD2 
synthase mRNA fragment, as well as specific primers for a 
457-bp fragment from the housekeeping gene GaPdH as a 
loading and integrity control. The first step of cDNA synthesis 
was carried out in a final volume of 50 µl using the Illustra™ 
Ready-To-Go™ RT-PCR Bead kit (GE Healthcare) and 1 µl of 
random hexamers pd(n)6 (12 pmol/µl) at 43˚C. In the second 
step, 1 µl of the forward and reverse primers was added. To 
optimize the rT-Pcr, we evaluated several parameters that 
are known to influence the outcome of this type of assay. After 
optimization, a typical 50-µl reaction included 2 µl RNAse 
Out (80 U; Invitrogen), 2 µl Mg2+ (25 mM; Promega) and 1 µl 
DTT (1 mM; Invitrogen). Amplification was carried out for 
60 cycles with a 63.7˚C annealing temperature. We also tested 
different types of first-strand primers during the reverse tran-
scription stage, such as pd(T)12-18 (0.5 µg/µl), the reverse PCR 
primer, and random hexamers pd(n)6, the latter being the best 
option. The optimal final concentration of primers used was 
0.24 pmol/µl. A final volume of 50 µl was completed with 
dePc-treated water. We used 5 ng rna from the Y79 human 
rB cell line as a template for each optimization round. Pcr 
products were analyzed by electrophoresis on 2% agarose gels 
followed by ethidium bromide staining.
RT-PCR and nested-PCR assay. For each rT-Pcr reaction, 
both a loading and integrity control (GaPdH) and a negative 
control (without template) were used, as well as a positive 
GD2 amplification control (5 ng of total RNA from Y79). For 
patient samples, 25 µl total RNA was employed as a template 
for the Gd2 analysis (regardless of the rna concentration 
obtained), and 4 µl total RNA was used for GAPDH ampli-
fication. Second round (nested-PCR) reactions consisted of 
a 1-µl aliquot of the first round reaction mix as a template, 
1 µl (12 pmol/µl) of each specific nested primer and 27 µl 
Platinum® PCR Supermix (Invitrogen) in a 30-µl final reac-
tion volume. Finally, 45 µl of the first round reaction volume 
and 30 µl of the second were subjected to electrophoresis in 
the agarose gels.
The cycling profile for the first round of amplification was 
carried out as follows: reverse transcription, 1 h at 43˚C; initial 
denaturation, 5 min at 95˚C; amplification (60 cycles), 1 min 
at 95˚C, 1 min at 63.7˚C and 30 sec at 72˚C; final extension, 
10 min at 72˚C. For the second round, cycling consisted of: 
initial denaturation, 1 min at 95˚C; amplification (30 cycles), 
30 sec at 95˚C, 30 sec at 60.2˚C and 30 sec at 72˚C; final 
extension, 5 min at 72˚C.
Results
in order to determine whether the putative marker, Gd2 
synthase, was present in an in vivo context, we first tested the 
expression of the Gd2 synthase product, the Gd2 ganglioside, 
using a xenograft model by means of an immunohistochem-
ical method as indirect evidence of enzyme expression in 
tumors. For this purpose, Y79 cells were injected into the 
flank of nude mice with culture medium or Matrigel to allow 
for tumor development. animals developed subcutaneous rB 
tumors with a latency of 12 or 4 days, and a volume of ~250 
or 1,000 mm3 at 25 days after inoculation, for medium or 
Matrigel injection, respectively. Evaluation with the specific 
anti-GD2 antibody 3F8 confirmed the abundant expression of 
the ganglioside in the cell membranes and cytoplasm of the 
Y79 tumor cells (Fig. 1a). other portions of the same tumors 
were subjected to RNA extraction and subsequently analyzed 
by an appropriately optimized RT-PCR assay. The first round 
of amplification detected an almost identical GD2 synthase 
mrna level as in the positive control in the xenograft tumors 
generated either with or without Matrigel (Fig. 1B).
after achieving an easily visible band of the expected size 
for the target amplicon in 2% agarose gels, we accomplished 
the optimization process of the rT-Pcr assay for the Gd2 
synthase mrna (Materials and methods). The sensitivity 
and specificity of the optimized assay was determined by 
analyzing serially reduced amounts of template, starting from 
Table I. Primers for amplification of GD2 synthase and GAPDH mRNA sequences.
mrna Forward primer reverse primer Product size (bp)
Gd2
  rT-Pcr 5'-TcGGcTacGGcTcTcaTcaccaG-3' 5'-cTGaGcGTGGaGcccGGcG-3' 347
  Nested-PCR 5'-GAACCTGGCCGTGTCTCAAGTAAC-3' 5'-CACCACTTATCGGCAGCTGCT-3' 180
GaPdH
  rT-Pcr 5'-GGGGaGccaaaaGGGTcaTcaTcT-3' 5'-GacGccTGcTTcaccaccTTcTTG-3' 457
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5 ng of total rna obtained from human rB cells as well as 
from other tumor cell lines. as shown in Fig. 2a, we detected 
the Gd2 synthase transcript when using at least 200 pg of total 
RNA from the Y79 cells in the first amplification reaction. 
This sensitivity was further improved by nested amplifica-
tion, in which the Gd2 synthase transcript was detected 
when using 40 pg total rna. in both rounds, the products 
obtained showed their predicted sizes (347 bp in the first and 
180 bp in the second round of amplification). Similar results 
were obtained with the Weri-rb1 cell line. using the same 
amount of total rna (5 ng), we also observed Gd2 synthase 
mRNA amplification in human carcinoma cell lines (Fig. 2B). 
In all cases, RNA integrity was confirmed by RT-PCR using 
specific primers for GAPDH mRNA.
We subsequently tested eight tumor bank samples from 
different rB patients in order to preliminarily examine 
the potential clinical value of the present rT-Pcr assay in 
detecting disseminated tumor cells. Six of these patients had 
no histopathology risk factors on examination, one patient had 
stage 2 disease due to tumor invasion of the optic nerve at 
the resection margin as well as microscopical choroid inva-
sion, while the remaining patient had stage 4a disease due to 
bone marrow metastasis (30). in this patient, the optic nerve 
stump was also involved. The patient with stage 2 disease, 
who was hence at high risk of relapse, presented no target 
amplification in PB in the first round of RT-PCR. However, 
when nested-Pcr was performed, a clear Gd2 synthase band 
was detected (Fig. 3a, lane b2). He was treated with adjuvant 
systemic chemotherapy and orbital irradiation according 
to the institutional protocol (31), and has been in complete 
remission for 25 months. The patient with stage 4a disease had 
Gd2-positive cells by immunocytology in the bone marrow 
(data not shown) and showed a faint band corresponding to 
GD2 synthase mRNA visible in the first round of RT-PCR 
amplification in the CSF sample at diagnosis and a clear band 
in the nested-PCR (Fig. 3C, lane csf8). Neither cytological 
examination of the cSF centrifugate nor immunocytology 
for Gd2 detected tumor cells. no PB sample was available at 
the tumor bank for this patient. The patient was treated with 
intensive chemotherapy including autologous stem cell rescue, 
but relapsed in the cSF 11 months post-transplantion and 
succumbed to resistant disease. By contrast, none of the other 
PB samples, which were derived from patients who did not 
present histological high-risk features, were positive for Gd2 
synthase after rT-Pcr or nested-Pcr (Fig. 3a).
We also analyzed the expression of Gd2 synthase in human 
tumor samples from another three patients from the tumor 
bank in order to verify whether Gd2 synthase was expressed 
as in the cell lines. as shown in Fig. 3B, only one sample was 
Figure 1. (A) Immunohistochemical detection of GD2 ganglioside in paraffin-
embedded material from a Y79 xenograft tumor generated with Matrigel in 
the subcutis of nude mice. (B) Gd2 synthase expression tested by rT-Pcr in 
human Y79 retinoblastoma tumors generated in nude mice. lane +M, rna 
extracted from a Y79 tumor generated by co-injection with Matrigel; lane 
-M, rna extracted from a Y79 tumor generated by co-injection with culture 
medium alone without Matrigel; lane Gd2+, positive control (5 ng of total 
rna from Y79 cultured cells).
Figure 2. In vitro sensitivity and specificity of the RT-PCR assay. (A) 
detection of human Gd2 synthase mrna in a serial 1:5 dilution of total 
rna obtained from the Y79 retinoblastoma cell line. (B) detection of the 
target sequence in human carcinoma and retinoblastoma cell lines using 
5 ng of total rna as a template. lane 1, Weri-rb1 retinoblastoma; lane 2, 
McF7 breast carcinoma; lane 3, Hela cervical carcinoma; lane 4, H125 lung 
carcinoma; lane 5, Y79 retinoblastoma cell lines. rT-Pcr products were 
analyzed by 2% agarose gel electrophoresis and dyed with ethidium bromide 
(experimental details in Materials and methods).
Figure 3. Molecular detection of Gd2 synthase mrna by rT-Pcr and 
nested-Pcr in samples from rB patients. a total of eight samples from eight 
different cases were available for analysis. (a) Blood samples, lanes b1-b4. 
(B) Tumor samples, lanes t5-t7. (C) CSF sample, lane csf8. In all cases, the 
GAPDH sequence was used as a control for the load and integrity of the 
rna. Gd2+, positive control (5 ng of total rna from Y79 cultured cells) 
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positive in the first round of amplification (lane t7). Using a 
second round of amplification, all tumor samples were posi-
tive for Gd2 synthase, as expected (Fig. 3B).
in addition, we checked target mrna expression in PB 
samples obtained from eight healthy adult donors. all samples 
were negative for Gd2 synthase mrna expression after either 
the first or second round of amplification (Fig. 4).
Discussion
In the present study, we detected for the first time the expres-
sion of Gd2 synthase mrna in rB cell lines and tumor 
samples from rB patients. The presence of Gd2 synthase and 
the GD2 ganglioside in RB tumors was also confirmed by 
rT-Pcr and immunohistochemical assays using a xenograft 
model. despite the fact that one of the three tumor samples 
was positive in the first round of amplification, the other two 
required a second round for the detection of GD2 synthase 
mrna. This may have been due to a poor harvest of viable 
cells during tumor sampling. in this regard, the relationship 
between the mrna level of glycosyltransferases and the 
presence of their products was established elsewhere (21). 
Therefore, as it is now routinely used for neuroblastoma, Gd2 
synthase may be a suitable molecular marker for the detection 
of Mdd in rB.
To the best of our knowledge, there have been few previous 
reports concerning the use of molecular markers for minimal 
residual disease (Mrd) assessment by rT-Pcr in rB. instead, 
other traditional techniques such as cytometric methods, 
standard light microscopy (32), immunocytochemistry/
cytology and fluorescence-activated flow cytometry (27) have 
been used for Mrd analysis in rB. 
Yamane et al (33) serially assessed, using rT-Pcr, the 
expression of the neuroendocrine protein gene product PGP9.5 
in PB mononuclear cells, bone marrow and mobilized PB stem 
cells from a single rB patient with metastatic disease. The 
aim was to use PGP9.5 expression as a predictable marker 
for detecting Mrd after intensive therapy and for evaluating 
therapeutic effects. However, the specificity of PGP9.5 gene 
transcripts in the detection of micrometastasis in blood and 
bone marrow in neuroblastoma was not convincing, since 
the marker was also found in control samples in another 
investigation (34). 
More recently, Yamashita et al (35) presented a case report 
of a patient with disseminated rB and evaluated three different 
gene sequences: cone α'-subunit of cGMP phosphodiesterase, 
rod β'-subunit of cGMP phosphodiesterase (rod β-Pde) and 
interphosphoreceptor retinoid-binding protein (irBP). The 
authors concluded that molecular detection of irBP is useful 
in cases of disseminated rB to ascertain the safety of stem cell 
transplantation, and that both irBP and rod β-Pde are more 
suitable for monitoring the effectiveness of chemotherapy. 
However, only case studies have been reported, and a large 
number of RB cases are needed to define the clinical utility 
of these and other molecular markers. Both reports dealt 
with the study of Mrd in patients with metastatic disease 
who underwent intensive treatment. However, this condi-
tion is very uncommon in our setting. Molecular markers of 
disseminated disease may be useful for detecting Mdd at 
diagnosis in patients with histopathological risk factors for 
extraocular relapse, and could aid the clinician in prescribing 
adjuvant therapy in these cases, which are common in devel-
oping countries such as argentina.
after optimizing our nested rT-Pcr assay, we achieved a 
final sensitivity for GD2 synthase mRNA detection of at least 
200 pg of total RNA in the first round of amplification, and 
40 pg in the second. in comparison with the aforementioned 
study on PGP9.5, irBP and rod β-Pde rT-Pcr detection, we 
obtained a much better sensitivity starting from an amount of 
rna template three orders scarcer. Thus, our optimization 
is a very good option for Mdd detection in rB, and should 
encourage others to continue this type of practice in rB or 
other malignancies. 
The sensitivity achieved allowed us to detect malignant rB 
cells in a particular PB sample through Gd2 synthase mrna 
amplification, a task that is often difficult as malignant cells 
circulate at low concentrations (36). The sample corresponded 
to a patient who had a tumor at the resection margin of the 
optic nerve after enucleation. no prognostic implications 
were drawn from this case since only samples from our tumor 
bank were used and there was no prospective follow-up. 
Furthermore, all blood samples from healthy volunteers were 
negative for Gd2 synthase, indicating that this mrna may be 
a valuable molecular marker for Mdd.
Molecular analysis is difficult in biological compartments 
such as cSF due to its low cellularity, but is potentially 
important since cSF is the most common site of the recurrence 
of metastatic retinoblastoma. Tumor-specific RT-PCR assays 
have been widely used for the detection of Mdd in several 
biological compartments, but this is the first time that RT-PCR 
and Gd2 synthase were successfully used to identify the 
presence of tumor cells in cSF in a patient with metastatic 
rB in bone marrow. While the use of Gd2 synthase as a 
marker for meningeal infiltration has been previously reported 
in neuroblastoma (37), to our knowledge it has never been 
described in rB.
The number of patients studied was an intrinsic limitation 
of our study and others. Thus, though suggestive, our data are 
insufficient to reliably demonstrate that the amplification of 
Gd2 synthase mrna is a valuable molecular marker for Mdd 
in rB. This marker is currently being prospectively evaluated 
in a larger cohort to confirm its usefulness. Moreover, the 
sensitivity and the prognostic value of Pcr-based assays for 
the detection of occult tumor cells can be improved by serial 
sampling and the use of multiple markers.
The ideal MDD marker is tumor specific; it should not 
be expressed in normal compartments such as bone marrow 
or PB. However, the potential molecular marker that we 
Figure 4. Gd2 synthase expression tested by rT-Pcr and nested-Pcr in 
peripheral blood samples from healthy adult volunteers. Blood samples were 
designated b9-b16. In all cases, the GAPDH sequence was used as a control for 
the load and integrity of the rna. Gd2+, positive control (5 ng of total rna 
from Y79 cultured cells) (experimental details in Materials and methods).
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investigated in this report has been found to be expressed in 
normal tissues. Indeed, recent publications confirm this fact 
and propose the utilization of other molecular markers instead 
(38,39). Quantitative RT-PCR (qRT-PCR) is an indispensable 
tool for the determination of the threshold between normal 
and abnormal expression of any type of marker. certainly, the 
development of real-time qRT-PCR is valuable for monitoring 
cancer progression (40), and is currently being carried out at 
our laboratory for this particular molecular marker. despite 
the ubiquitous character of the enzyme, its expression level is 
low and, to be detected, it requires a system with very high 
sensitivity. Again, qRT-PCR will prove useful in determining 
a threshold at which levels of Gd2 synthase expression 
become clearly abnormal.
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